Zoetis. has filed a patent for injectable pharmaceutical compositions that effectively preserve the medication. The compositions contain water soluble complexes, preservatives, and co-solvents, and meet the criteria for antimicrobial preservation set by the European Pharmacopoeia and the United States Pharmacopeia. GlobalData’s report on Zoetis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zoetis, Personalized cancer vaccines was a key innovation area identified from patents. Zoetis's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Injectable pharmaceutical compositions with effective antimicrobial preservation
A recently filed patent (Publication Number: US20230293550A1) describes a method for anesthetizing animals using an injectable pharmaceutical composition. The composition must comply with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation and meet the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing for Category 1 (injectable) products.
The composition includes water, alfaxalone (at a concentration of 1% w/v to 5% w/v), 2-hydroxypropyl-ß-cyclodextrin (at a concentration of 8% w/v to 40% w/v), chlorocresol (at a concentration of 0.1% w/v to 0.15% w/v), and ethanol (at a concentration of 15% w/v). Additionally, a phosphate-based buffer can be added to maintain a pH range of 6.0 to 7.5. The phosphate-based buffer may consist of disodium phosphate and potassium dihydrogen phosphate.
The composition may also contain benzethonium chloride (at a concentration of 0.005% w/v to 0.05% w/v) and sodium chloride. The alfaxalone can be present in the composition at a concentration of either 1% w/v or 4% w/v.
The method is applicable to mammals, specifically cats and dogs.
This patent application outlines a method for anesthetizing animals using a specific injectable pharmaceutical composition. The composition must meet certain standards for antimicrobial preservation and effectiveness. It includes various ingredients such as alfaxalone, 2-hydroxypropyl-ß-cyclodextrin, chlorocresol, and ethanol. A phosphate-based buffer can be added to maintain the desired pH range. The composition may also contain benzethonium chloride and sodium chloride. The method is specifically designed for anesthetizing mammals, particularly cats and dogs.
It is important to note that this summary is based solely on the information provided in the patent application and does not include any additional context or analysis.
To know more about GlobalData’s detailed insights on Zoetis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
